



# BERGENBIO ASA: INVITATION TO THIRD QUARTER 2021 RESULTS PRESENTATION AND WEBCAST

**Bergen, Norway, 4 November 2021** – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, will be announcing its results for the third quarter 2021 on Tuesday 16 November 2021. The briefing will take place at 10:00 am CET at:

Carnegie AS, Fjordalleen 16, Aker Brygge, 5th Floor, Oslo

where BerGenBio's senior management team will provide an update on the Company followed by a Q&A session. To attend in person please register by mail to [hanna.haug@carnegie.no](mailto:hanna.haug@carnegie.no)

The presentation will webcast live and a link will be available at [www.bergenbio.com](http://www.bergenbio.com) in the Investors/Financial Reports section. A recording will be available shortly after the webcast has finished.

The third quarter report and presentation will be available on the Company's website in the Investors/Financial Reports section from 7:00 am CET the same day.

-Ends-

## Contacts

Martin Olin  
Chief Executive Officer, BerGenBio ASA  
[ir@bergenbio.com](mailto:ir@bergenbio.com)

Rune Skeie  
Chief Financial Officer, BerGenBio ASA  
[rune.skeie@bergenbio.com](mailto:rune.skeie@bergenbio.com)

## International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications  
[bergenbio@consilium-comms.com](mailto:bergenbio@consilium-comms.com)  
+44 20 3709 5700

## About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme focused on combination

and single agent therapy in cancer and COVID-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is developing companion diagnostic test to identify patient populations most likely to benefit from AXL inhibition. This is expected to facilitate more efficient registration trials supporting a precision medicine-based commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit [www.bergenbio.com](http://www.bergenbio.com)

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.